Crossmark

Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial

Crossref DOI link: https://doi.org/10.1186/s12906-023-04283-3

Published Online: 2023-12-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ha, Na-Yeon

Kim, Jung-Wook

Kim, Jinsung
Funding

Funding for this research was provided by:

Korea Health Industry Development Institute (HI20C0865)
License Information

Text and Data Mining valid from 2023-12-07

Version of Record valid from 2023-12-07
More Information

Article History

Received: 24 October 2023

Accepted: 28 November 2023

First Online: 7 December 2023

Declarations

:

: The clinical trial protocol was approved by the IRB of Kyung Hee University Korean Medicine Hospital (IRB File No.: 2020–05-007, June 3, 2020). The study protocol was registered with the Clinical Research Information Service (CRIS) (Version 2.1, registration number: KCT0008600). Any amendments to a previously completed protocol will be resubmitted, approved, and documented in the IRB and CRIS. Based on the ethical principles and relevant regulations of the Declaration of Helsinki, a detailed explanation of the clinical trial process will be provided to the participants by the PI and authorized researchers in accordance with legal procedures. The participants will be required to sign an informed consent form of their own free will before participating in the clinical trial.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below